JP2024534550A - 抗体の新規組み合わせ及びその使用 - Google Patents

抗体の新規組み合わせ及びその使用 Download PDF

Info

Publication number
JP2024534550A
JP2024534550A JP2024518167A JP2024518167A JP2024534550A JP 2024534550 A JP2024534550 A JP 2024534550A JP 2024518167 A JP2024518167 A JP 2024518167A JP 2024518167 A JP2024518167 A JP 2024518167A JP 2024534550 A JP2024534550 A JP 2024534550A
Authority
JP
Japan
Prior art keywords
antibody molecule
antibody
ctla
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534550A5 (cg-RX-API-DMAC10.html
Inventor
フレンデウス ビョルン
レーン マティルダ
セムリッチ モニカ
モルテンソン リンダ
マルシャン ジャン－バティスト
Original Assignee
バイオインベント インターナショナル アクティエボラーグ
トランジェヌ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオインベント インターナショナル アクティエボラーグ, トランジェヌ ソシエテ アノニム filed Critical バイオインベント インターナショナル アクティエボラーグ
Publication of JP2024534550A publication Critical patent/JP2024534550A/ja
Publication of JP2024534550A5 publication Critical patent/JP2024534550A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024518167A 2021-09-22 2022-09-21 抗体の新規組み合わせ及びその使用 Pending JP2024534550A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21306310 2021-09-22
EP21306310.0 2021-09-22
EP22305050.1 2022-01-18
EP22305050 2022-01-18
PCT/EP2022/076268 WO2023046777A1 (en) 2021-09-22 2022-09-21 Novel combinations of antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534550A true JP2024534550A (ja) 2024-09-20
JP2024534550A5 JP2024534550A5 (cg-RX-API-DMAC10.html) 2025-09-08

Family

ID=83507478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518167A Pending JP2024534550A (ja) 2021-09-22 2022-09-21 抗体の新規組み合わせ及びその使用

Country Status (10)

Country Link
US (1) US20240374719A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405050A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534550A (cg-RX-API-DMAC10.html)
KR (1) KR20240067076A (cg-RX-API-DMAC10.html)
AU (1) AU2022351060A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231396A1 (cg-RX-API-DMAC10.html)
IL (1) IL311234A (cg-RX-API-DMAC10.html)
MX (1) MX2024003578A (cg-RX-API-DMAC10.html)
TW (1) TW202321458A (cg-RX-API-DMAC10.html)
WO (1) WO2023046777A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2833425T3 (es) * 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020049001A1 (en) * 2018-09-03 2020-03-12 Bioinvent International Ab Novel antibodies and nucleotide sequences, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
RU2489486C2 (ru) 2006-06-20 2013-08-10 Трансжене С.А. Процесс получения поксвирусов и композиции поксвирусов
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
AU2008250596C1 (en) 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
DK2212345T3 (en) 2007-11-19 2016-03-21 Transgene Sa Oncolytic poxvirus vectors
AU2009214768B2 (en) 2008-02-12 2015-01-22 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
KR102022952B1 (ko) 2011-08-05 2019-09-20 신라젠(주) 백시니아 바이러스의 생산을 위한 방법 및 조성물
WO2018170133A1 (en) * 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN118892540A (zh) * 2017-04-21 2024-11-05 新罗杰股份有限公司 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
WO2019178101A1 (en) * 2018-03-13 2019-09-19 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
TW202102543A (zh) * 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020049001A1 (en) * 2018-09-03 2020-03-12 Bioinvent International Ab Novel antibodies and nucleotide sequences, and uses thereof

Also Published As

Publication number Publication date
WO2023046777A8 (en) 2023-05-11
IL311234A (en) 2024-05-01
US20240374719A1 (en) 2024-11-14
MX2024003578A (es) 2024-04-03
TW202321458A (zh) 2023-06-01
WO2023046777A1 (en) 2023-03-30
CA3231396A1 (en) 2023-03-30
EP4405050A1 (en) 2024-07-31
AU2022351060A1 (en) 2024-04-11
KR20240067076A (ko) 2024-05-16

Similar Documents

Publication Publication Date Title
US20230348602A1 (en) Novel anti-pd-1 antibodies
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
AU2018360800A1 (en) Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
CN111196852A (zh) 抗tigit抗体及其用途
TW202237658A (zh) 抗ｔｎｆｒ２人源化抗體及其用途
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
EP4445912A1 (en) P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereof
CN111108124A (zh) 新型抗体以及treg消耗性抗体和免疫刺激性抗体的组合使用
US20250257135A1 (en) Novel antibodies and nucleotide sequences, and uses thereof
CN115038718A (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
WO2021155830A1 (en) Anti-hpv t cell receptors and engineered cells
TW202328171A (zh) 靶向NKp46之經修飾之IL-2多肽及其用途
JP2018502068A (ja) 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用
US20240374719A1 (en) Novel combinations of antibodies and uses thereof
WO2021244653A1 (en) Tcr-t cell therapy targeting epstein-barr virus
JP2025526677A (ja) Ｂ７－ｈ３抗原結合性分子
HK40106416A (en) Novel combinations of antibodies and uses thereof
JP2024500511A (ja) 抗ｐｄ－ｌ１抗体及びその使用
CN118176016A (zh) 抗体的新型组合及其用途
HK40115595A (en) Novel antibodies and nucleotide sequences, and uses thereof
JP2026508096A (ja) 治療抗体
HK40095521A (en) Novel combinations of antibodies and uses thereof
CN119661712A (zh) 特异性结合tnfr2的抗体及其应用
CN116963745A (zh) 抗体的新型组合及其用途
BR112018002824B1 (pt) Anticorpo isolado ou um fragmento de ligação, kit, usos do anticorpo e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260701